Part II | Chapter 8 178 References 1. Ward JF, Pagliaro LC, Pisters LL. Salvage Therapy for Radiorecurrent Prostate Cancer. Curr Probl Cancer 2008;32:242–71. 2. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of longterm outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33. 3. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015;67:1009–16. 4. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis of Intraprostatic Failures in Patients Treated With Hormonal Therapy and Radiotherapy : Implications for Conformal Therapy Planning. Int J Radiat Oncol Biol Phys 2002;53:595–9. 5. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically Significant Prostate Cancer Local Recurrence After Radiation Therapy Occurs at the Site of Primary Tumor: Magnetic Resonance Imaging and Step-Section Pathology Evidence. Int J Radiat Oncol Biol Phys 2007;69:62–9. 6. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, et al. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med 2016;41:515–21. 7. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11–20. 8. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, et al. Anatomic Patterns of Recurrence Following Biochemical Relapse in the Dose-Escalation Era for Prostate Patients Undergoing External Beam Radiotherapy. J Urol 2015;194:1624–30. 9. Khoo CC, Miah S, Connor MJ, Tam J, Winkler M, Ahmed HU, et al. A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer. Transl Androl Urol 2020;9:1535–45. 10. Van Son M, Peters M, Moerland M, Kerkmeijer L, Lagendijk J, Van der Voort van Zyp J. Focal salvage treatment of radiorecurrent prostate cancer: A narrative review of current strategies and future perspectives. Cancers 2018;10:480. 11. van Son MJ, Peters M, Moerland MA, Lagendijk JJW, Eppinga WSC, Shah TT, et al. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localised Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. Int J Radiat Oncol 2020;107(1):126-135. 12. Stabile A, Orczyk C, Giganti F, Moschini M, Allen C, Punwani S, et al. The Role of Percentage of Prostatespecific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multiinstitutional Series. Eur Urol 2020;78(2):155-160. 13. Tan WP, ElShafei A, Aminsharifi A, Khalifa AO, Polascik TJ. Salvage Focal Cryotherapy Offers Similar Shortterm Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer. Clin Genitourin Cancer 2019:260–5. 14. Bomers JGR, Overduin CG, Jenniskens SFM, Cornel EB, van Lin ENJT, Sedelaar JPM, et al. Focal Salvage MR Imaging–Guided Cryoablation for Localised Prostate Cancer Recurrence after Radiotherapy: 12-Month Follow-up. J Vasc Interv Radiol 2020;31:35–41. 15. Duijzentkunst DAS, Peters M, van der Voort van Zyp JRN, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol 2016;34:1521–31. 16. Henríquez I, Sancho G, Hervás A, Guix B, Pera J, Gutierrez C, et al. Salvage brachytherapy in prostate local recurrence after radiation therapy: Predicting factors for control and toxicity. Radiat Oncol 2014;9:1– 8. 17. Peters M, Kanthabalan A, Shah TT, McCartan N, Moore CM, Arya M, et al. Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient progn. Urol Oncol Semin Orig Investig 2018;36:13.e1-13.e10. 18. Peters M, van der Voort van Zyp JRN, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, et al. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. Brachytherapy 2016;15:296–305.
RkJQdWJsaXNoZXIy MTk4NDMw